The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Sana Biotechnology

Sana Biotechnology (NASDAQ: SANA) focuses on creating and delivering engineered cells as medicines for patients.

Sana Biotechnology Headquarters Location

188 East Blaine Street Suite 400

Seattle, Washington, 98102,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Sana Biotechnology

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Sana Biotechnology in 3 CB Insights research briefs, most recently on Aug 4, 2020.

Expert Collections containing Sana Biotechnology

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sana Biotechnology is included in 2 Expert Collections, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

Sana Biotechnology Patents

Sana Biotechnology has filed 4 patents.

The 3 most popular patent topics include:

  • Biotechnology
  • Clusters of differentiation
  • Immune system
patents chart

Application Date

Grant Date


Related Topics



Transcription factors, Membrane biology, Protein domains, Clusters of differentiation, Molecular biology


Application Date


Grant Date


Related Topics

Transcription factors, Membrane biology, Protein domains, Clusters of differentiation, Molecular biology



Latest Sana Biotechnology News

Complexity is the attraction: Steve Harr on the pull of cell and gene therapy

Aug 12, 2022

Complexity is the attraction: Steve Harr on the pull of cell and gene therapy Sana CEO tells The BioCentury Show his approach to making a step difference in the field By C. Simone Fishburn, Editor in Chief August 11, 2022 11:57 AM UTC Cell therapy and gene therapy aren’t distinct opportunities in Steve Harr’s eyes. Rather, the platform he is building as president and CEO of Sana is one that combines the two, and capitalizes on the collective knowledge and experience of the Juno graduates who found themselves wanting to do more, after the company’s acquisition by Celgene. On The BioCentury Show, Harr discussed his view of how the cell and gene therapy field is evolving, and both the technical and talent challenges that will be required to drive success at scale. Harr launched   Sana Biotechnology Inc. (NASDAQ:SANA) together with Chairman Hans Bishop in January 2019, with ambitious goals to fix any cell in the body that’s been damaged, replace any cell that’s too far damaged, and have “access never determined by where a patient is born,” he said. The company has made a splash, announcing $700 million in venture financing in 2020, and going public a year later with one of the biggest IPOs  in biotech history, raising $675.6 million. Bishop had been president and CEO of Juno Therapeutics Inc. and Harr CFO and head of corporate development, leading the deal with Celgene Corp. that closed in March 2018. Celgene was acquired by Bristol Myers Squibb Co. (NYSE:BMY) in November 2019. Harr said that after the acquisition, many of the Juno team felt there was unfinished business, not having gotten drugs across the finish line, and there was momentum to work together again. He said the complexity of the goal was the attraction, but it was not simple to work out the best operating model. “If there’s ever a book written on Sana, Chapter One will be about the decision we made out of the gate, which was to start the company to build our capabilities more or less at equal size and scale across three different cities: Seattle, San Francisco, and Cambridge.”  That allowed them to tap into different talent pools, but also added further challenges in what is already a complex area. “History will be the judge,” as to whether it was a good decision or not, said Harr. Purchase Reprint/Distribution Rights

Sana Biotechnology Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Sana Biotechnology Rank

  • When was Sana Biotechnology founded?

    Sana Biotechnology was founded in 2018.

  • Where is Sana Biotechnology's headquarters?

    Sana Biotechnology's headquarters is located at 188 East Blaine Street, Seattle.

  • What is Sana Biotechnology's latest funding round?

    Sana Biotechnology's latest funding round is IPO.

  • How much did Sana Biotechnology raise?

    Sana Biotechnology raised a total of $700M.

  • Who are the investors of Sana Biotechnology?

    Investors of Sana Biotechnology include F-Prime Capital, Flagship Pioneering, ARCH Venture Partners, WRF Capital, Amity Ventures and 14 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.